UCB - Cost Of Sales

Stock Price
225.60
Daily Change
-2.10 -0.92%
Monthly
-10.97%
Yearly
39.99%
Q2 Forecast
233.96

UCB reported EUR1.07B in Cost of Sales for its fiscal semester ending in December of 2025.





Cost Of Sales Change Date
Alcon AG USD 1.2B 46M Dec/2025
Almirall EUR 191.5M 2.29M Dec/2025
Amarin USD 26.05M 1.41M Dec/2025
argenx SE USD 149.69M 40.26M Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
Bayer EUR 4.5B 194M Dec/2025
Galapagos EUR 455K 84.28M Dec/2025
Genmab DKK 81M 23M Dec/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
GRIFOLS EUR 1.29B 163.12M Dec/2025
Hikma Pharmaceutical USD 959M 492.5M Dec/2025
Lonza CHF 2.28B 189M Jun/2025
Merck EUR 2.29B 183M Dec/2025
Novartis USD 3.54B 3M Dec/2025
Orion EUR 163.7M 22.9M Mar/2026
Recordati EUR 199.91M 20.12M Sep/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sanofi EUR 3.67B 621M Mar/2026
UCB EUR 1.07B 146M Dec/2025
Unibail Rodamco EUR 546.4M 9.4M Dec/2025